Phase 4 N=48 Effect of Methylnaltrexone on GI Transit in Healthy Volunteers
Gastric Motility Disorder
Primary: Colonic Geometric Center at 24 Hours — 2.3; 1.8; 1.9; 2.3 Units on a scale — p=0.902
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=38 Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans
Effects of 2 Mu-opiates on Gastrointestinal Transit
Primary: Colonic Transit, Geometric Center at 24 Hours — 2.06; 2.07; 2.17 units on a scale
Phase 2 N=131 Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Opioid Induced Constipation
Primary: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment — 1.96; 3.42; 1.44 Number of SBMs/week
Phase 2 N=81 Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Constipation
Primary: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment — 1.40; 2.58 Number of SBMs/week
N/A N=52 Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable Bowel Syndrome · Constipation
Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours
Phase 4 N=12 Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation
Constipation Drug Induced
Primary: Occurrence of Bowl Movement — 2; 2; 5 Participants
Phase 3 N=50 A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery
Postoperative Pain · Postoperative Nausea and Vomiting
Primary: Prevalence of Postoperative Gut Dysfunction — 13; 15 Participants — p=0.264
N/A N=100 Effect of Electroacupuncture on Opioid-induced Constipation in Patients With Cancer
Opioid-induced Constipation in Patients With Cancer
Primary: Number of Participants With Response — 19; 4 participants
Phase 2 N=82 Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention
Postoperative Ileus
Primary: Time to First Bowel Movement — 61.8; 50.7 hours — p=0.81
Phase 4 N=22 Effect of Dexmedetomidine of Gastrointestinal Motility
Anesthesia
Primary: Intra-anal Sphincter Pressure (IASP) 1 Minute After Dexmedetomidine Administration — 62.9 mmHg
Phase 4 N=30 Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine
Coronary Artery Disease
Primary: Platelet Reactivity Measured by VerifyNow P2Y12 — 130; 97 PRU — p=0.261
Phase 3 N=37 Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation
Chronic Idiopathic Constipation
Primary: Time Reduction (Hours and Minutes) of Gastric Emptying (GE), Small Bowel (SB), Large Bowel (LB) and Whole Gut (WG) Transits Measured by SmartPill in Chronically…
Phase 4 N=10 Brain Effects of Opiate Agonist and Antagonist
Chronic Low-back Pain
Primary: Mean Change in Subcortical Brain Structure Volume — 0.054; 0.74; 0.27; 0.48 cubic centimeters — p=>0.05
Phase 4 N=25 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75
Phase 2 N=40 Naloxone SR Capsules in Patients With Opioid Induced Constipation
Chronic Pain · Opioid Induced Constipation
Primary: Incidence and Severity of Treatment Emergent Adverse Events on Single Dosing. — 8; 5; 4; 6 participants
N/A N=27 The Effects of Minocycline in Opioid-maintained Patients
Opioid Dependence · Pain
Primary: Pain Threshold — 18.72; 24.78; 16.16; 24.37 seconds
Phase 2 N=36 Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome
Primary: Colonic Transit Geometric Center at 24 Hours — 3.12; 3.05; 2.77 units on a scale
Phase 3 N=40 Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility
Healthy
Primary: Gastric Volume — 262; 718 mL — p=<0.0001
Phase 4 N=230 Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
Opioid-Induced Constipation
Primary: The Proportion of Subjects Who Have a Rescue-free Laxation Response Within 4 Hours After at Least 2 of the First 4 Doses — 62.9; 9.6 percentage of participants — p=<…
N/A N=293 Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia
Labor Pain · Post-cesarean Delivery
Primary: Duration of Intrathecal Fentanyl Analgesia — 70; 63 Minutes — p=0.54
Phase 2 N=36 Cheno Effect on Transit in Health and IBS-C
Constipation-predominant Irritable Bowel Syndrome
Primary: Colonic Geometric Center at 24 Hours (GC24) — 3.1; 3.5; 2.2 units on a scale
Phase 1 N=41 Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.
Chronic Constipation, Methanogenesis
Primary: Change in Methane Production — 10645; 14635 parts per million*minutes
Phase 2 N=12 Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
Neoplasms · Constipation · Opioid-Related Disorders
Primary: Rescue-free Laxation After Administration of Subcutaneous Methylnaltrexone — 33 percentage of participants
Phase 3 N=146 Accelerating Gastrointestinal Recovery
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Postoperative Length of Hospital Stay — 4.4; 4.3 days — p=0.34
Phase 2 N=79 Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Gastroparesis
Primary: Gastric Half Emptying Time (GEt1/2) — 131.2; 106.5; 118.2; 131.1 Minutes
Phase 4 N=120 Methadone and Hydromorphone For Spinal Surgery
Hydromorphone Use · Acute Postoperative Pain · Patient Satisfaction
Primary: Hydromorphone Use at 24 Hours — 4.56; 9.9 milligrams
Phase 4 N=19 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003
Phase 3 N=50 Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation
Constipation
Primary: The Proportion of Subjects Having a Rescue-free Bowel Movement (RFBM) Within 4 Hours After the First Injection. — 79.2; 4.3 percentage of participants — p=<0.0001
Phase 2 N=128 Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain
Constipation
Primary: Percentage of Participants Witn Spontaneous Bowel Movements Within 3 Hours of Treatment — 2; 3; 2; 5 Participants
Phase 1 N=28 To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers
Common Cold
Primary: Mean Time to Onset of Gastric Emptying — 1.107; 8.534 minutes